Want to see TRVI full AI Analyst Report?
TRVI Stock Chart & Stats
$13.47
<$0.01(0.12%)
At close: 4:00 PM EST
$13.47
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$9.82 - $20.22
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.38M
Market Cap
$1.70B
Enterprise Value$2.60B
Total Cash (Recent Filing)$318.87M
Total Debt (Recent Filing)$605.00K
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding142,475,850
10 Day Avg. Volume3,728,275
30 Day Avg. Volume2,381,442
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)9.91
Price to Sales (P/S)0.00
P/FCF Ratio-43.15
Enterprise Value/Market Cap1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-76.54K
Enterprise Value/Ebitda-50.99
Forecast
1Y Price Target
$29.00Price Target Upside115.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stronger Equity BaseVery low leverage and a materially larger equity base provide financial flexibility for a clinical-stage company. This reduces balance-sheet strain and may support continued development investment, although operating performance remains dependent on future progress toward commercialization.
Focused Multi-indication PipelineThe company has a clearly defined development focus around Haduvio for chronic cough and pruritus, with studies spanning multiple indications. A shared product platform across these areas could broaden potential development opportunities without requiring an entirely separate pipeline for each target.
Improving Free Cash Flow TrendAlthough free cash flow remains negative, the improvement in the TTM figure is a modest constructive trend. If maintained, lower cash consumption could extend financial flexibility and reduce the pace at which the company must fund ongoing clinical development.
Bears Say
No Revenue GenerationTRVI remains pre-revenue, so its business model has not yet demonstrated recurring commercial sales. This leaves future financial performance dependent on converting the development pipeline into approved, marketable products and creates substantial execution risk before revenue can support operations.
Persistent High Cash BurnSustained operating and free-cash-flow deficits show that the company continues to consume substantial cash while developing its therapies. Ongoing funding needs can constrain capital allocation and make financial flexibility increasingly dependent on the available equity base and future financing.
Widening TTM Losses And Negative ReturnsThe TTM loss widened again after a smaller 2025 loss, indicating that expenses remain substantial ahead of revenue generation. Deeply negative returns show that the current asset and equity base is not yet producing economic returns, weakening the sustainability of the financial model.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $9.82 and its highest was $20.22 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $1.70B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.109 by -$0.001.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.13.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 142,475,850 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.109. Following the earnings report the stock price went up 0.054%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (115.29% Upside)
$29.00 (115.29% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.86%
12-Months-Change
Fundamentals
Return on Equity
-23.59%
Trailing 12-Months
Asset Growth
58.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
TRVI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid execution progress: a strengthened balance sheet (pro forma cash ~ $334M) with runway into 2030, positive FDA alignment for IPF-related chronic cough, near-term trial initiations (Phase III IPF, Phase IIb RCC), an adaptive plan for non-IPF-ILD pending FDA agreement, expansion of IP filings and active scientific visibility (ATS, Investor Day). Principal risks discussed include competitor P2X3 readouts, possible trial upsizing via SSRE (and associated costs/timing), placebo variability in RCC, and regulatory dependence for the non-IPF-ILD program. On balance, the company presented multiple material positives and manageable risks tied to execution and external competitive/regulatory factors.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$29.00
▲(115.29% Upside)
Technical Analysis
Palvella Therapeutics
―
Aclaris Therapeutics
―
MoonLake Immunotherapeutics
―
Alumis Inc.
―
Alamar Biosciences, Inc.
―
Ownership Overview
1.31% Insiders
16.75% Mutual Funds
3.54% Other Institutional Investors
67.73% Public Companies and
Individual Investors